CHARLES PATRICK REYNOLDS

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Retinoid therapy of high-risk neuroblastoma
    C Patrick Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
    Cancer Lett 197:185-92. 2003
  2. ncbi request reprint Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide
    C P Reynolds
    Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA
    Med Pediatr Oncol 35:597-602. 2000
  3. ncbi request reprint Assessing combinations of cytotoxic agents using leukemia cell lines
    C Patrick Reynolds
    Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Department of Pediatrics, Keck School of Medicine, University of Southern California and Childrens Hospital Los Angeles, CA 90027, USA
    Curr Drug Targets 8:765-71. 2007
  4. ncbi request reprint Detection and treatment of minimal residual disease in high-risk neuroblastoma
    C Patrick Reynolds
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Childrens Hospital Los Angeles, CA 90027, USA
    Pediatr Transplant 8:56-66. 2004
  5. ncbi request reprint Ceramide synthesis and metabolism as a target for cancer therapy
    C Patrick Reynolds
    Division of Hematology Oncology MS 57, Children s Hospital of Los Angeles, The University of Southern California Keck School of Medicine, 4650 Sunset Blvd, Los Angeles, CA 90054 0700, USA
    Cancer Lett 206:169-80. 2004
  6. ncbi request reprint Differentiating agents in pediatric malignancies: retinoids in neuroblastoma
    C P Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and The University of Southern California School of Medicine, 4650 Sunset Boulevard Los Angeles, CA 90054 0700, USA
    Curr Oncol Rep 2:511-8. 2000
  7. ncbi request reprint Retinoid therapy of childhood cancer
    C P Reynolds
    Developmental Therapeutics Section, Division of Hematology Oncology, Children s Hospital of Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California, USA
    Hematol Oncol Clin North Am 15:867-910. 2001
  8. ncbi request reprint Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
    Sandeep Batra
    Division of Hematology Oncology, Children s Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Cancer Res 64:5415-24. 2004
  9. ncbi request reprint A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
    Tomas Frgala
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Children s Hospital Los Angeles, MS 57, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Mol Cancer Ther 6:886-97. 2007
  10. ncbi request reprint Tirapazamine cytotoxicity for neuroblastoma is p53 dependent
    Bo Yang
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Division of Hematology Oncology, Children s Hospital Los Angeles, California
    Clin Cancer Res 11:2774-80. 2005

Research Grants

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Retinoid therapy of high-risk neuroblastoma
    C Patrick Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
    Cancer Lett 197:185-92. 2003
    ..Thus, further clinical trials of 4-HPR in neuroblastoma, and of 4-HPR in combination with ceramide modulators, are warranted...
  2. ncbi request reprint Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide
    C P Reynolds
    Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA
    Med Pediatr Oncol 35:597-602. 2000
    ..High-dose, pulse-13-cis-retinoic acid (13-cis-RA) given after intensive cytotoxic therapy improves event-free survival for high-risk neuroblastoma (NB), but more than 50% of patients have tumor recurrence...
  3. ncbi request reprint Assessing combinations of cytotoxic agents using leukemia cell lines
    C Patrick Reynolds
    Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Department of Pediatrics, Keck School of Medicine, University of Southern California and Childrens Hospital Los Angeles, CA 90027, USA
    Curr Drug Targets 8:765-71. 2007
    ..to be the most suitable for evaluating of drug interactions in cell culture assays...
  4. ncbi request reprint Detection and treatment of minimal residual disease in high-risk neuroblastoma
    C Patrick Reynolds
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Childrens Hospital Los Angeles, CA 90027, USA
    Pediatr Transplant 8:56-66. 2004
    ..18-IL2 immunocytokine. It is anticipated that testing novel approaches to treating neuroblastoma MRD will be the subject of future phase-III randomized trials...
  5. ncbi request reprint Ceramide synthesis and metabolism as a target for cancer therapy
    C Patrick Reynolds
    Division of Hematology Oncology MS 57, Children s Hospital of Los Angeles, The University of Southern California Keck School of Medicine, 4650 Sunset Blvd, Los Angeles, CA 90054 0700, USA
    Cancer Lett 206:169-80. 2004
    ..Thus, pharmacological manipulation of sphingolipid metabolism to enhance tumor cell ceramide is being realized and offers a novel approach to cancer chemotherapy...
  6. ncbi request reprint Differentiating agents in pediatric malignancies: retinoids in neuroblastoma
    C P Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and The University of Southern California School of Medicine, 4650 Sunset Boulevard Los Angeles, CA 90054 0700, USA
    Curr Oncol Rep 2:511-8. 2000
    ....
  7. ncbi request reprint Retinoid therapy of childhood cancer
    C P Reynolds
    Developmental Therapeutics Section, Division of Hematology Oncology, Children s Hospital of Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California, USA
    Hematol Oncol Clin North Am 15:867-910. 2001
    ..Clinical trials of fenretinide, alone and in combination with ceramide modulators, are in development...
  8. ncbi request reprint Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators
    Sandeep Batra
    Division of Hematology Oncology, Children s Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Cancer Res 64:5415-24. 2004
    ....
  9. ncbi request reprint A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
    Tomas Frgala
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Children s Hospital Los Angeles, MS 57, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Mol Cancer Ther 6:886-97. 2007
    ..Using DIMSCAN, a fluorescence digital image system for quantifying relative cell numbers in tissue culture plates, we have developed a 96-well cytotoxicity assay with a >4-log dynamic range...
  10. ncbi request reprint Tirapazamine cytotoxicity for neuroblastoma is p53 dependent
    Bo Yang
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Division of Hematology Oncology, Children s Hospital Los Angeles, California
    Clin Cancer Res 11:2774-80. 2005
    ..These data further define the mechanism of action of TPZ and suggest that as a single agent, TPZ would only have clinical activity against p53-functional neuroblastomas...
  11. ncbi request reprint Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody
    Rita S Grigoryan
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Los Angeles, California 90027, USA
    Cytometry A 71:951-60. 2007
    ..These data demonstrate that Mab F7-26 recognized ssDNA due to exogenous DNA damage, rather than apoptosis. This assay should be useful to characterize the mechanism of action of antineoplastic drugs...
  12. ncbi request reprint Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53
    Nino Keshelava
    Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 9:3492-502. 2003
    ....
  13. ncbi request reprint Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine
    Bo Yang
    Division of Hematology Oncology, Children s Hospital Los Angeles, California 90027, USA
    Cancer Res 63:1520-6. 2003
    ..These data additionally define the role of ROS in BSO-mediated cytotoxicity and suggest that combining BSO with TPZ could have clinical activity against NB in hypoxic sites...
  14. ncbi request reprint The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation
    Hongjun Peng
    Division of Hematology Oncology, Department of Pediatrics, University of Southern California, USA
    Cancer Res 67:9346-55. 2007
    ....
  15. ncbi request reprint DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy
    Nino Keshelava
    USC CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 110:139-53. 2005
    ..DIMSCAN has been used to demonstrate preclinical activity of cytotostatic and cytotoxic drugs and drug combinations that have subsequently shown activity in clinical trials...
  16. ncbi request reprint Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines
    Hiroaki Goto
    Divisions of Hematology Oncology and Research Immunology Bone Marrow Transplantation, Childrens Hospital Los Angeles, CA 90027, USA
    Mol Cancer Ther 2:911-7. 2003
    ..Our data suggest caution when employing GFP-transduced cells to assess drug sensitivity and that using a cell surface antigen as a selection marker for gene transduction may perturb cells less than GFP...
  17. ncbi request reprint Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide
    Nino Keshelava
    Institute for Pediatric Clinical Research and Division of Hematology Oncology, Childrens Hospital Los Angeles, University of South California, Los Angeles, CA 90027, USA
    J Natl Cancer Inst 99:1107-19. 2007
    ..Genes that are overexpressed in multidrug-resistant neuroblastomas relative to drug-sensitive neuroblastomas may provide targets for modulating drug resistance...
  18. doi request reprint Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation
    Min H Kang
    Division of Hematology Oncology, USC CHLA Institute for Pediatric Clinical Research, Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
    J Natl Cancer Inst 100:580-95. 2008
    ..Thus, we investigated whether 4-HPR-mediated inactivation of Mcl-1 could act synergistically with ABT-737 to promote leukemia cell death...
  19. ncbi request reprint Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
    Min H Kang
    Developmental Therapeutics Program, Childrens Hospital Los Angeles and University of Southern California Institute for Pediatric Clinical Research, Los Angeles, CA 90027, USA
    Blood 110:2057-66. 2007
    ..Combining VXL with a BH3-mimetic warrants clinical investigation in ALL at relapse and potentially in chemotherapy-resistant ALL subgroups...
  20. ncbi request reprint Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex
    Barry J Maurer
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research and Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA
    Clin Cancer Res 13:3079-86. 2007
    ..To support the hypothesis that a novel organized lipid matrix, LYM-X-SORB, can increase the oral bioavailability of fenretinide, fenretinide in LYM-X-SORB matrix and in a powderized LYM-X-SORB formulation was delivered to mice...
  21. pmc Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
    Nino Keshelava
    Children s Hospital of Los Angeles, Los Angeles, California 90027, USA
    Pediatr Blood Cancer 53:505-8. 2009
    ..Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers...
  22. ncbi request reprint Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)
    Judith G Villablanca
    Children s Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA
    J Clin Oncol 24:3423-30. 2006
    ..To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors...
  23. ncbi request reprint Ceramide signaling in fenretinide-induced endothelial cell apoptosis
    Anat Erdreich-Epstein
    Division of Hematology Oncology, Department of Pediatrics, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    J Biol Chem 277:49531-7. 2002
    ..Our results provide the first evidence that increased ceramide biosynthesis is required for 4-HPR-induced endothelial apoptosis and present a molecular mechanism for its antiangiogenic effects...
  24. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma...
  25. ncbi request reprint Assessing growth and response to therapy in murine tumor models
    C Patrick Reynolds
    USC CHLA Institute of Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, USA
    Methods Mol Med 111:335-50. 2005
    ....
  26. ncbi request reprint Evaluating response to antineoplastic drug combinations in tissue culture models
    C Patrick Reynolds
    USC CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 110:173-83. 2005
    ..We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays...
  27. doi request reprint Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity
    Theresa M Harned
    Developmental Therapeutics Program, USC CHLA Institute for Pediatric Clinical Research, Keck School of Medicine, University of Southern California and Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
    Clin Cancer Res 14:533-40. 2008
    ....
  28. ncbi request reprint Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate
    Yasuyoshi Sohara
    Department of Pediatrics, Division of Hematology Oncology, Childrens Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
    Cancer Res 63:3026-31. 2003
    ..The data suggest that bisphosphonates may be clinically effective in the treatment of bone metastases in neuroblastoma...
  29. ncbi request reprint GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma
    Stephen S Roberts
    Department of Pediatrics, NRC 5, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    J Clin Oncol 22:4127-34. 2004
    ..Neuroblastoma (NB) is a common childhood malignancy characterized by heterogeneous clinical behavior. The purpose of this study was to identify potential NB biomarkers that may improve outcome prediction...
  30. ncbi request reprint In vitro testing of chemosensitivity in physiological hypoxia
    Rita Grigoryan
    Developmental Therapeutics Section, Children s Hospital of Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 110:87-100. 2005
    ..We review the impact of hypoxia on anticancer drug cytotoxicity and the methods used in our laboratory to asses the cytotoxic activity of single antineoplastic drugs under conditions of physiological hypoxia...
  31. pmc Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
    Liping Song
    Division of Hematology Oncology, Department of Pediatrics, Childrens Hospital Los Angeles CHLA, Los Angeles, California 90027, USA
    J Clin Invest 117:2702-12. 2007
    ....
  32. pmc Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
    Julie R Park
    Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
    Pediatr Blood Cancer 52:44-50. 2009
    ..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial...
  33. doi request reprint Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial
    Eric Cheung
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    Clin Genitourin Cancer 7:43-50. 2009
    ..Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer...
  34. ncbi request reprint Metabolism of orthotopic mouse brain tumor models
    Michael Rosol
    Department of Radiology, Division of Hematology Oncology, Saban Research Institute at Children s Hospital Los Angeles, USA
    Mol Imaging 8:199-208. 2009
    ..The causes of these dissimilarities warrant further investigation...
  35. ncbi request reprint E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase
    Hyung Gyoo Kang
    Department of Pathology and Laboratory Medicine, USC CHLA Institute for Pediatric Clinical Research, Los Angeles, California, USA
    Cancer Res 67:3094-105. 2007
    ....
  36. ncbi request reprint Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophi
    Leonid S Metelitsa
    Department of Pediatrics, Division of Hematology Oncology, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles 90027, USA
    Blood 99:4166-73. 2002
    ..Thus, hu14.18/GM-CSF facilitates PMN ADCC against neuroblastoma cells associated with FcgammaRII and Mac-1-dependent enhanced adhesion and degranulation...
  37. doi request reprint Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells
    Hyung Gyoo Kang
    Department of Pathology and Laboratory Medicine, Children s Hospital Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 9:1396-407. 2010
    ..EGCG may be a useful agent for targeting IGFIR, either alone or in combination, with other potentially more toxic IGFIR inhibitors for the management of EFTs...

Research Grants1

  1. Xenograft models of human neuroblastoma bone metastases.
    Charles Reynolds; Fiscal Year: 2004
    ..We anticipate that this project will increase our understanding of the biology of bone metastases and will develop mouse models for pre-clinical testing of new therapeutic approaches to high risk neuroblastoma. ..